Pathologic Complete Response: How can the I-SPY2 study results benefit patients with HR+ HER2- Breast Cancer? Laura Huppert MD - Synopsis below extracted from the video transcript.
HER2 Low Breast Cancer: What Are the Latest Advancements in Novel Drug Antibody Conjugates for 2023? Yuan Yuan, MD - Synopsis below extracted from the video transcript
Recent developments in our profession, including antibody drug conjugates notably Trastuzumab Deruxtecan, a monoclonal antibody in HER2 low illness, have significantly altered our perception of breast cancer. We previously classified breast cancer as triple-negative, HER2-positive, and ER positive. Now the HER2 low has eliminated the old barrier and put them into the non-HER2 low category, which is really exciting.